Novel xenograft and cell line derived from an invasive intraductal papillary mucinous neoplasm of the pancreas give new insights into molecular mechanisms

Pancreas

Volumn 39, Issue 3, 2010, Pages 308-314

  Fritz, Stefan ^a   Fernández Del Castillo, Carlos ^a   Iafrate, A John ^a   Mino Kenudson, Mari ^a   Neyhard, Nancy ^a   Lafemina, Jennifer ^a   Stirman, Amy ^a   Warshaw, Andrew L ^a   Thayer, Sarah P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cell line; Genetic characterization; Intraductal papillary mucinous neoplasms; Pancreas; Xenograft

Indexed keywords

K RAS PROTEIN; PROTEIN P53; SONIC HEDGEHOG PROTEIN;

ADULT; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; KARYOTYPING; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TETRAPLOIDY; XENOGRAFT;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENES, TUMOR SUPPRESSOR; HEDGEHOG PROTEINS; HUMANS; MALE; MICE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); VERATRUM ALKALOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950295231     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bd5c10     Document Type: Article

References (32)

1. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678-685; discussion 685-687.
2. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg. 2001;234:313-321; discussion 321-322.
3. Conlon KC. Intraductal papillary mucinous tumors of the pancreas. J Clin Oncol. 2005;23:4518-4523.
4. Fernández-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138:427-433; discussion 433-434.
5. Sarr MG, Murr M, Smyrk TC, et al. Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. J Gastrointest Surg. 2003;7:417-428.
6. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788-797; discussion 797-799.
7. Wada K, Kozarek RA, Traverso LW. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2005;189:632-636; discussion 637.
8. Volkan Adsay N. Cystic lesions of the pancreas. Mod Pathol. 2007;20(suppl 1):S71YS93.
9. Sato N, Goggins M. Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg. 2006;13:280-285.
10. Salvia R, Crippa S, Falconi M, et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut. 2007;56:1086-1090.
11. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17-32.
12. Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol. 2000;24:1372-1377.
13. Adsay NV, Conlon KC, Zee SY, et al. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer. 2002;94:62-77.
14. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123:1500-1507.
15. D'Angelica M, Brennan MF, Suriawinata AA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg. 2004;239:400-408.
16. Kitagawa Y, Unger TA, Taylor S, et al. Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg. 2003;7:12-18; discussion 18-19.
17. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10-15.
18. Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27: 324-329.
19. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586-594.
20. Adsay NV, Longnecker DS, Klimstra DS. Pancreatic tumors with cystic dilatation of the ducts: intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms. Semin Diagn Pathol. 2000;17:16-30.
21. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an Bintestinal[ pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839-848.
22. Fukushima N, Sakamoto M, Mukai K, et al. Intraductal papillary components in invasive ductal carcinoma of the pancreas are associated with long-term survival of patients. Hum Pathol. 2001;32:834-841.
23. Furukawa T, Kloppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794-799.
24. Fujii H, Inagaki M, Kasai S, et al. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 1997;151:1447-1454.
25. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol. 2000;157:755-761.
26. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
27. Waldman FM, DeVries S, Chew KL, et al. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst. 2000;92:313-320.
28. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949-951.
29. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218-1249.
30. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425:851-856.
31. Kato M, Shimada Y, Tanaka H, et al. Characterization of six cell lines established from human pancreatic adenocarcinomas. Cancer. 1999;85:832-840.
32. Sorio C, Bonora A, Orlandini S, et al. Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch. 2001;438: 154-158.